Zealand Pharma is a publicly traded Danish biotechnology company listed on Nasdaq under the ticker ZEAL. The company focuses on the discovery, design, and development of peptide-based medicines, with a clinical pipeline centred on metabolic diseases, obesity, and metabolic health. It has advanced more than ten drug candidates through its research programmes.
Technical work at Zealand Pharma spans peptide drug development, biotechnology, and metabolic diseases research. The company's R&D operations are supported by offices in Copenhagen, Denmark, as well as in Boston and Cambridge, Massachusetts, reflecting a strategic expansion of its scientific capabilities.
The company operates across the biotechnology, pharmaceuticals, and metabolic disease therapeutics sectors. Its stated commitment centres on developing treatments for conditions including obesity, drawing on deep scientific expertise in peptide chemistry and drug design.
